Learning Objectives:

• Describe the key pharmacologic updates in the 2026 ADA Standards of Care, including individualized approaches to treatment selection for glucose lowering and optimization of cardio-kidney-metabolic health
• Explain the expanded role of diabetes technology in type 2 diabetes management, including updated recommendations for continuous glucose monitoring (CGM) initiation and use, reduced barriers to automated insulin delivery systems, and practical considerations for integrating these technologies into primary care practice.
• Apply updated guideline recommendations to clinical decision-making through case-based examples that illustrate individualized pharmacotherapy and technology selection for patients with type 2 diabetes, including considerations for patient preferences, comorbidity profiles, and risk stratification.